Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from non-alcoholic fatty liver and non-alcoholic steatohepatitis to its more severe forms such as liver fibrosis and cirrhosis. The incidence of hepatocellular carcinoma (HCC) increases as NAFLD progresses to the more severe...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/83341 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from non-alcoholic fatty liver and non-alcoholic steatohepatitis to its more severe forms such as liver fibrosis and cirrhosis. The incidence of hepatocellular carcinoma (HCC) increases as NAFLD progresses to the more severe forms. As prevalence of obesity and metabolic syndrome rising in North America, NAFLD associated HCC is becoming the leading cause of HCC. Different from other causes of HCC, altered metabolic state and its impact on immune response play an important role in the pathogenesis of NAFLD associated HCC. Currently, immune checkpoint inhibitors and combination therapy are first-line treatments of advanced HCC regardless of etiologies. Given the rising incidence of NAFLD associated HCC and its unique pathogenesis, future clinical trials should assess whether HCC etiology—NAFLD in particular—influence the safety and efficacy of a given treatment. |
|---|---|
| ISBN: | 978-1-80356-413-5 |
| DOI: | 10.5772/intechopen.106816 |